Scalper1 News
British pharma giant GlaxoSmithKline (GSK) reported a mediocre Q1 and issued fairly bullish long-term guidance Wednesday morning, as it announced it’s keeping its HIV unit after all. Its stock rose about 1% in midday trading. Glaxo’s earnings in the quarter declined 16% from the year-earlier quarter to 17.30 pounds a share, missing analysts’ consensus of 17.36, according to Thomson Reuters. In U.S. terms, profit dropped 27% to 51 cents per Scalper1 News
Scalper1 News